Biotech · Public company · Lakeway, TX, US
Anebulo Pharmaceuticals, Inc.
Ticker ANEB · SEC CIK 0001815974
Track this companyFree. Adds Anebulo Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline1
- selonabantPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- I.V. Selonabant in Healthy Adult SubjectsPHASE1 · COMPLETED · started Sep 22, 2025ClinicalTrials.gov NCT07211607 · fetched Nov 12, 2026
- Observational Study of THC Concentrations in Acute Cannabis-induced CNS DepressionRECRUITING · started Jun 1, 2023ClinicalTrials.gov NCT06017622 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Feb 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 22, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 13, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 13, 2025 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Sep 29, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 29, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 12, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 23, 2025 · fetched Nov 12, 2026
NIH awards2
- Development of an intravenous CB1 antagonist for acute cannabinoid intoxication and cannabis hyperemesis syndromeFiscal year 2025 · $994.3KNIH RePORTER 5U01DA059995-02 · fetched Nov 12, 2026
- Development of an intravenous CB1 antagonist for acute cannabinoid intoxication and cannabis hyperemesis syndromeFiscal year 2024 · $892.3KNIH RePORTER 1U01DA059995-01 · fetched Nov 12, 2026